Sun Pharma announced the commercial launch of Drizalma Sprinkle (duloxetine delayed-release capsules), a serotonin and norepinephrine reuptake inhibitor (SNRI).
Drizalma Sprinkle is indicated for: major depressive disorder (MDD) in adults; generalized anxiety disorder (GAD) in patients aged 7 to 17 years; diabetic peripheral neuropathic pain (DPNP) in adults; and chronic musculoskeletal pain in adults.
The new sprinkle formulation is designed for patients with difficulty swallowing as the capsules may be opened and the contents emptied over a tablespoonful of applesauce; the mixture should be swallowed immediately without chewing. The product can also be swallowed whole or administered via nasogastric tube.
Drizalma Sprinkle is available in 20mg, 30mg, 40mg, or 60mg capsule strengths in 30-, 60-, 90-, and 1000-count bottles. Each capsule contains enteric-coated pellets designed to prevent degradation of the drug in the acidic environment of the stomach.
Regarding safety, Drizalma Sprinkle carries a Boxed Warning for suicidal thoughts and behaviors. The most common adverse reactions associated with treatment include nausea, dry mouth, somnolence, constipation, decreased appetite, and hyperhidrosis.
“The launch of Drizalma Sprinkle is an important milestone for people with difficulty swallowing, as this formulation of duloxetine can facilitate treatment of common neuro-psychiatric disorders while preserving the quality of the medicine,” said Abhay Gandhi, CEO, North America, Sun Pharma. ”This launch further underscores our commitment to providing a portfolio of alternative formulation products to treat common diseases – especially in long-term care, where 30-35% of individuals have difficulty swallowing.”
Additionally, Sun Pharma’s portfolio includes Ezallor Sprinkle (rosuvastatin) and Kapspargo Sprinkle (metoprolol succinate extended-release) capsules designed for patients with swallowing difficulties.
For more information visit dizalmasprinkle.com.